Ciprofloxacin Prophylaxis in High Risk Neutropenic Patients: Effects on Outcomes, Antimicrobial Therapy and Resistance

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2013 Aug 1

PMID 23899356

Citations 19

Authors

Marcia Garnica

Simone A Nouer

Flavia L P C Pellegrino

Beatriz M Moreira

Angelo Maiolino

Marcio Nucci

Affiliations

Soon will be listed here.

Abstract

Background: The use of quinolone prophylaxis in high-risk neutropenic patients is considered standard of care but the development of resistance is a concern. Previous studies have focused mainly on quinolone resistance among patients receiving prophylaxis, with very few data reporting its impact on the hospital microbial epidemiology.

Methods: We analyzed a cohort of 329 episodes of chemotherapy-induced neutropenia in adults, and compared two periods: 2005 (period 1, no prophylaxis, n=110) and 2006-2008 (period 2, ciprofloxacin prophylaxis, n=219). Outcomes analyzed were the frequency of febrile neutropenia, bacteremia, duration of antibiotic therapy and hospitalization, and antimicrobial resistance to ciprofloxacin and extended-spectrum beta-lactamase [ESBL] production. We analyzed resistance rates (by patients-day) in the cohort, as well as in other patients (neutropenic and non-neutropenic, 11,975 patients-day) admitted to the hematology unit in the same period, taking into consideration the general resistance patterns in the hospital.

Results: Quinolone prophylaxis (period 2) resulted in fewer episodes of febrile neutropenia (159/219 [73%] vs. 102/110 [93%], Chi-square 18.09, p = 0.00002), and bacteremia (49/219 [22] vs. 36/110 [33%], Chi-square 4.10, p = 0.04), shorter duration of antibiotic therapy (p = 0.0002) and hospitalization (p = 0.002), but more frequent use of carbapenems (79/219 [36%] vs. 15/110 [14%], Chi-square 18.06, p = 0.0002). In addition, period 2 was associated with higher rates of quinolone resistance (6.77 vs. 3.02 per 1,000 patients-day, p = 0.03). The rate of ESBL-producing enterobacteria in the two periods was slightly higher in patients receiving quinolone prophylaxis (1.27 vs. 0.38 per 1,000 patients-day, p = 0.26) as well as in the hematology unit overall (1.59 vs. 0.53 per 1,000 patients-day, p = 0.08), but remained stable in the whole hospital (0.53 vs. 0.56 per 1,000 patients-day, p = 0.74).

Conclusions: Ciprofloxacin prophylaxis was beneficial in high risk neutropenic patients, but important modifications in the prescription of carbapenems and on antimicrobial resistance patterns of isolates were observed. The importance of hospital or ward ecology must be taken into account when deciding for quinolone prophylaxis in high-risk neutropenic patients.

Citing Articles

The effect of ciprofloxacin prophylaxis during haematopoietic cell transplantation on infection episodes, exposure to treatment antimicrobials and antimicrobial resistance: a single-centre retrospective cohort study.

Baltas I, Kavallieros K, Konstantinou G, Koutoumanou E, Gibani M, Gilchrist M JAC Antimicrob Resist. 2024; 6(1):dlae010.

PMID: 38304723 PMC: 10833646. DOI: 10.1093/jacamr/dlae010.

The Dutch Working Party on Antibiotic Policy (SWAB) Recommendations for the Diagnosis and Management of Febrile Neutropenia in Patients with Cancer.

de la Court J, Bruns A, Roukens A, Baas I, van Steeg K, Toren-Wielema M Infect Dis Ther. 2022; 11(6):2063-2098.

PMID: 36229765 PMC: 9669256. DOI: 10.1007/s40121-022-00700-1.

Bloodstream Infections in Patients with Hematologic Diseases: Causative Organisms and Factors Associated with Resistance.

Choi H, Ahn H, Lee R, Cho S, Lee D Infect Chemother. 2022; 54(2):340-352.

PMID: 35794719 PMC: 9259903. DOI: 10.3947/ic.2022.0069.

Efficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia-A Single Center Analysis.

Modemann F, Harterich S, Schulze Zur Wiesch J, Rohde H, Lindeman N, Bokemeyer C Antibiotics (Basel). 2022; 11(2).

PMID: 35203731 PMC: 8868403. DOI: 10.3390/antibiotics11020128.

Periodontal inflamed surface area in oral cavity associated with febrile neutropenia in patients with hematologic malignancy undergoing chemotherapy.

Nishi H, Ohta K, Kuramoto Y, Shigeishi H, Obayashi T, Yoshioka Y Sci Rep. 2022; 12(1):2483.

PMID: 35169215 PMC: 8847642. DOI: 10.1038/s41598-022-06485-0.

References

Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A . Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer. 2006; 107(8):1743-51. DOI: 10.1002/cncr.22205. View

Gafter-Gvili A, Fraser A, Paul M, Leibovici L . Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005; 142(12 Pt 1):979-95. DOI: 10.7326/0003-4819-142-12_part_1-200506210-00008. View

Paterson D, Mulazimoglu L, Casellas J, Ko W, Goossens H, von Gottberg A . Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis. 2000; 30(3):473-8. DOI: 10.1086/313719. View

Reuter S, Kern W, Sigge A, Dohner H, Marre R, Kern P . Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies. Clin Infect Dis. 2005; 40(8):1087-93. DOI: 10.1086/428732. View

Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011; 52(4):427-31. DOI: 10.1093/cid/ciq147. View

Lautenbach E, Strom B, Bilker W, Patel J, Edelstein P, Fishman N . Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis. 2001; 33(8):1288-94. DOI: 10.1086/322667. View

Trecarichi E, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P . Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009; 58(4):299-307. DOI: 10.1016/j.jinf.2009.02.002. View

Mahenthiralingam E, CAMPBELL M, Foster J, Lam J, Speert D . Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol. 1996; 34(5):1129-35. PMC: 228968. DOI: 10.1128/jcm.34.5.1129-1135.1996. View

Gales A, Castanheira M, Jones R, Sader H . Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis. 2012; 73(4):354-60. DOI: 10.1016/j.diagmicrobio.2012.04.007. View

10.

Cremet L, Caroff N, Dauvergne S, Reynaud A, Lepelletier D, Corvec S . Prevalence of plasmid-mediated quinolone resistance determinants in ESBL Enterobacteriaceae clinical isolates over a 1-year period in a French hospital. Pathol Biol (Paris). 2009; 59(3):151-6. DOI: 10.1016/j.patbio.2009.04.003. View

11.

Wener K, Schechner V, Gold H, Wright S, Carmeli Y . Treatment with fluoroquinolones or with beta-lactam-beta-lactamase inhibitor combinations is a risk factor for isolation of extended-spectrum-beta-lactamase-producing Klebsiella species in hospitalized patients. Antimicrob Agents Chemother. 2010; 54(5):2010-6. PMC: 2863615. DOI: 10.1128/AAC.01131-09. View

12.

Jarlier V, Nicolas M, Fournier G, Philippon A . Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis. 1988; 10(4):867-78. DOI: 10.1093/clinids/10.4.867. View

13.

Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M . Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli. Cancer. 2003; 97(2):419-24. DOI: 10.1002/cncr.11044. View

14.

Craig M, Cumpston A, Hobbs G, Devetten M, Sarwari A, Ericson S . The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant. 2007; 39(8):477-82. DOI: 10.1038/sj.bmt.1705591. View

15.

Versalovic J, Koeuth T, Lupski J . Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. Nucleic Acids Res. 1991; 19(24):6823-31. PMC: 329316. DOI: 10.1093/nar/19.24.6823. View

16.

Oliveira A, de Souza M, Carvalho-Dias V, Ruiz M, Silla L, Tanaka P . Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007; 39(12):775-81. DOI: 10.1038/sj.bmt.1705677. View

17.

. From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. J Infect Dis. 1990; 161(3):397-401. DOI: 10.1093/infdis/161.3.397. View

18.

Humphries R, Bobenchik A, Hindler J, Schuetz A . Overview of Changes to the Clinical and Laboratory Standards Institute M100, 31st Edition. J Clin Microbiol. 2021; 59(12):e0021321. PMC: 8601225. DOI: 10.1128/JCM.00213-21. View

19.

Gafter-Gvili A, Paul M, Fraser A, Leibovici L . Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother. 2006; 59(1):5-22. DOI: 10.1093/jac/dkl425. View

20.

Chong Y, Yakushiji H, Ito Y, Kamimura T . Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis. 2011; 15(4):e277-81. DOI: 10.1016/j.ijid.2010.12.010. View